ADENOSINE DEAMINASE, ADA-PLEURAL FLUID

Adenosine Deaminase (ADA) – Pleural Fluid is a biochemical test that measures adenosine deaminase activity in fluid collected from the pleural cavity. The pleural cavity is the thin space between the lungs and the inner chest wall. An abnormal accumulation of fluid in this space is known as a pleural effusion.

ADA is an enzyme involved in purine metabolism and is particularly associated with lymphocytes, which participate in cell-mediated immunity. ADA activity may increase when tuberculosis affects the pleural lining. Therefore, pleural-fluid ADA is commonly used as a supportive investigation when tuberculous pleural effusion is suspected. It does not independently confirm tuberculosis and must be interpreted with the patient’s symptoms and other test results.

Benefits of the Test

• Measures ADA activity directly in pleural fluid.
• Supports the evaluation of suspected tuberculous pleural effusion.
• May help differentiate tuberculous effusion from certain non-tuberculous effusions.
• Provides quantitative information about cellular immune activity.
• Can be performed with routine pleural-fluid investigations.
• May provide supportive information while culture results are awaited.
• Helps guide the selection of further microbiological or tissue investigations.
• Supports the evaluation of unexplained fluid around the lungs.
• Can assist clinical decision-making when interpreted with imaging and fluid-cell counts.
• Requires only a portion of fluid collected during a medically indicated procedure.

Why Doctors Recommend This Test

Doctors may recommend pleural-fluid ADA testing when a patient has a pleural effusion accompanied by prolonged fever, persistent cough, chest discomfort, breathing difficulty, night sweats, reduced appetite, or unexplained weight loss. It may be particularly helpful when pleural tuberculosis is suspected but initial sputum or microbiological investigations are inconclusive.

Preparation Before Test

• Fasting may be required depending on the planned fluid-collection procedure.
• Follow the doctor’s instructions regarding food, water, and medicines.
• Inform the doctor about blood-thinning medicines or bleeding disorders.
• Do not stop prescribed medicines without medical advice.
• Inform the doctor if you are pregnant or may be pregnant.
• Share any history of tuberculosis or recent tuberculosis exposure.
• Inform the doctor if anti-tuberculosis treatment has already been started.
• Carry previous chest X-ray, CT, ultrasound, sputum, or fluid-analysis reports.
• Pleural fluid must be collected by a trained medical professional using a sterile technique.
• Follow all breathing and positioning instructions during the procedure.

Normal Reporting Time

The Adenosine Deaminase, ADA – Pleural Fluid test is generally reported within a few working days after the sample is received, processed, analysed, validated, and reviewed. The exact reporting time may vary according to the testing schedule, analytical method, sample condition, and laboratory workflow.

Who Should Take This Test?

This test may be recommended for:

• Patients with an unexplained pleural effusion.
• Individuals being evaluated for suspected pleural tuberculosis.
• Patients with prolonged fever, cough, or breathing difficulty.
• Individuals with chest pain and unexplained weight loss.
• Patients with imaging findings suggestive of tuberculous pleural effusion.
• Individuals with lymphocyte-predominant pleural fluid.
• Patients with a history of tuberculosis or close tuberculosis exposure.
• Individuals with inconclusive sputum or initial fluid-test results.
• Patients requiring supportive testing while awaiting culture or biopsy results.
• People specifically advised to undergo pleural-fluid ADA testing by a specialist.

Detailed Information

The pleura consists of two thin tissue layers: one covers the lungs and the other lines the inside of the chest wall. A small amount of fluid normally allows these layers to move smoothly during breathing. Infection, inflammation, heart failure, liver disease, kidney disease, pulmonary embolism, or malignancy may cause excess fluid to collect between these layers.

Tuberculous pleural effusion occurs when Mycobacterium tuberculosis affects the pleural tissues and produces a strong cell-mediated immune response. This response involves T lymphocytes and other immune cells. Because ADA activity is closely associated with activated lymphocytes, the level may become elevated in tuberculous pleural fluid.

An elevated pleural-fluid ADA result can support the possibility of pleural tuberculosis, particularly when the fluid is an exudate with a high proportion of lymphocytes and the patient has compatible symptoms. However, an increased result cannot independently prove that tuberculosis is present.

Other conditions can also increase pleural-fluid ADA. These may include empyema, complicated bacterial pleural infection, lymphoma, rheumatoid pleuritis, certain malignancies, and other inflammatory disorders. The cell type present in the fluid, clinical history, imaging findings, and microbiological results are important for correct interpretation.

A low ADA result may make tuberculous pleural effusion less likely in an appropriate clinical setting, but it cannot completely rule it out. ADA levels can vary according to age, immune status, stage of disease, previous treatment, sample quality, laboratory method, and local tuberculosis prevalence.

The doctor may order pleural-fluid protein, glucose, albumin, lactate dehydrogenase, pH, total and differential cell counts, Gram staining, bacterial culture, acid-fast staining, mycobacterial culture, molecular testing, and cytology. Blood protein and lactate dehydrogenase may also be measured to classify the effusion as an exudate or transudate.

Mycobacterial culture may provide direct evidence of infection and allow further testing, but results can take several weeks. Molecular tests may detect mycobacterial genetic material more quickly, although a negative result does not always exclude pleural tuberculosis. In selected cases, pleural biopsy and histopathological examination may be required.

Reference values and diagnostic thresholds can differ according to the analytical method, patient population, and local prevalence of tuberculosis. The ADA result should therefore be interpreted using the reference information printed on the individual laboratory report.

The test does not identify tuberculosis drug resistance and cannot determine which medicines will be effective. If tuberculosis is detected or strongly suspected, additional microbiological investigations may be necessary for treatment planning.

At Focus Diagnostics, ADA Pleural Fluid testing is performed using established biochemical methods, appropriate sample-handling procedures, and laboratory quality controls to provide reliable results for clinical interpretation.